Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 6,323	$ 5,769	$ 17,165	$ 15,517
General and administrative	2,722	2,636	7,825	7,733
Total operating expenses	9,045	8,405	24,990	23,250
Loss from operations	(9,045)	(8,405)	(24,990)	(23,250)
Other income (expense):
Interest income, net	1,183	424	3,611	623
Other income, net	154		472
Interest expense	(3)	(292)	(387)	(889)
Change in fair value of term loan derivative liability				(147)
Total other income (expense), net	1,334	132	3,696	(413)
Loss before income taxes	(7,711)	(8,273)	(21,294)	(23,663)
Income tax benefit	13	7	50	16
Net loss	$ (7,698)	$ (8,266)	$ (21,244)	$ (23,647)
Basic net loss per common share outstanding	$ (0.08)	$ (0.12)	$ (0.21)	$ (0.44)
Diluted net loss per common share outstanding	$ (0.08)	$ (0.12)	$ (0.21)	$ (0.44)
Weighted average common shares used in net loss per share attributable to common stockholders, basic	99,325,540	68,898,810	98,880,882	53,221,949
Weighted average common shares used in net loss per share attributable to common stockholders, diluted	99,325,540	68,898,810	98,880,882	53,221,949
Net loss	$ (7,698)	$ (8,266)	$ (21,244)	$ (23,647)
Other comprehensive loss:
Net unrealized gains (losses) on available-for-sale marketable securities	31	(128)	(95)	(263)
Comprehensive loss	$ (7,667)	$ (8,394)	$ (21,339)	$ (23,910)